• 한국식품영양과학회지
• /
• 제38권12호
• /
• pp.1724-1731
• /
• 2009

마카, 홍삼, 남가새 추출물을 일정한 무게 비율로 혼합하여 발효시켜 얻어진 식물추출복합발효물(MP119)이 성기능에 미치는 영향을 조사하였다. ACE(angiotensin converting enzyme)과 PDE(phosphodiesterase)에 대한 저해효과를 통해 혈액순환부진 개선 및 cGMP 농도에 의한 발기능 개선에 미치는 효과를 측정하였다. MP119의 ACE 저해효과를 측정한 결과 $IC_{50}$값이 241.3${\pm}$35.5 ppm, PDE 저해효과를 측정한 결과 $IC_{50}$값이 372.2${\pm}$33.8 ppm으로 나타나 혈관확장으로 인한 혈류량 증가 및 cGMP농도 증가에 영향을 줄 수 있을 것으로 예상된다. MP119는 마우스 정소세포인 TM3 cell에 유의성 있는 독성이 나타나지 않았으며, TM3 cell에 농도별로 처리했을 때 세포배양액으로부터 대조군과 비교하여 최대 20.11% 증가한 testosterone 농도를 확인하였다. 또한 HUVEC에 농도별로 처리했을 때 NO생산량이 MP119 처리 농도가 증가할수록 유의성 있게 증가하였다. 웅성마우스에 MP119를 7일간 경구투여 후 생식장기의 무게와 정자수를 측정하고, MP119를 경구투여한 후 염화카드뮴을 투여하여 생식장기의 무게와 정자수를 측정하였다. 또한 실험쥐로부터 혈청을 분리하여 혈청 내 testosterone과 cGMP를 측정하였다. 그 결과 MP119의 투여를 통해 생식장기의 무게 변화 없이 정자수 증가에 도움을 준다는 것을 확인하였으며, 더불어 혈청 내 testosterone 및 cGMP의 농도 역시 증가하였다. MP119를 투여한 후 염화카드뮴을 투여한 실험군에서 역시 정자수 및 혈청 내 testosterone, cGMP 농도 증가를 나타내었으므로 결과적으로 MP119가 염화카드뮴의 독성예방 및 치료에 효과적임을 확인하였다.

• Applied Biological Chemistry
• /
• 제11권
• /
• pp.1-27
• /
• 1969

우리나라에서 알려진 젓갈 30여종(餘種)에서 그중(中) 대표적(代表的)인 것으로 알려진 조기젓. 조개젓(고식(高食) 염성(鹽性)인 20%내외(內外))과 굴젓, 오징어젓(저식염성(低食鹽性)인 10%내외(內外))의 4종(種)을 시료(試料)로하여 일반성분(一般成分) 분석(分析), microflora, 주요발효미생물(主要醱酵微生物)의 동정(同定) 및 효소(酵素)의 특성(特性)을 조사(調査)하는 동시(同時)에 숙성(熟成)에 관여(關與)하는 미생물(微生物)의 효소작용(酵素作用)이 정미성(呈味性) 5’-mononucleotide 및 amino 산(酸)의 생성(生成)에 미치는 영향(影響)을 조사(調査)하여 다음과 같은 결과(結果)를 얻었다. (1) 4종(種) 젓갈에 대(對)한 microflara를 조사(調査)한 결과(結果)는 다음과 같다. a) 젓갈담금 $1{\sim}2$개월(個月)의것은 생균수(生菌數) total counts가 $10^7$이었으며 담금후(後) 6개월(個月)의것은 $10^4$이였다. b) 젓 갈 담금 $1{\sim}2$개월(個月)의것은 Micrococcus 속(屬)이 $10{\sim}20%$, Brevibacterium 속(屬)이 $10{\sim}20%$, Sarcina 속(屬)이 $0{\sim}30%$, Leuconostoc 속(屬) $20{\sim}30%$, Bacillus 속(屬)이 30%내외(內外) Pseudomonas 속(屬)이 $0{\sim}10%$ Flavobacterium 속(屬)이 $0{\sim}10%$ Yeast가 $0{\sim}20%$인 분포상(分布相)을 나타냈다. c) 젓갈숙성(熟成)에 관여(關與)하는 미생물(微生物)로서 초기이후(初期以後)에는 주(主)로 내염성(耐鹽性) Bacillus subtilis, Leuconostoc mesenteroides, Pediococcus halophilus, Sarcina litoralis 등(等)임을 동정(同定)하였고 이들의 효소활성(酵素活性)이 젓갈숙성(熟成)을 지배(支配)하는 요소(要素)임을 알 수 있었다. d) 숙성(熟成)에 관여(關與)하는 세균중(細菌中)에 Sarcina litoralis 8­14 및 8-16. 양균주(兩菌株)는 영양요구성(榮養要求性)이 현저(顯著)하여 전자(前者)는 purine, pyrimidine base 및 cystine 후자(後者)는 purine, pyrimidine base 및 glutamic acid가 공존(共存)하여야 생육(生育)이 가능(可能)하였다. (2) 젓갈원료(原料) 및 젓갈에서 분리(分離)한 관여미생물(關與微生物)에 대(對)하여 효소특성(酵素特性)을 검토(檢討)한 결과(結果)는 다음과 같다. a) 젓갈원료중(原料中)에 protease는 소량(少量) 존재(存在)하나 식염농도(食鹽濃度) 7%에서 protease 활성(活性)이 현저(顯著)하게 조해(阻害)를 받아 그 효소활성(酵素活性)의 $30{\sim}60%$나 감소(減少)하였다. b) 내염성세균(耐鹽性細菌)인 Bacillus subtilis 7-6, 11-1, 3-6 9-4 등(等) 4 균주(菌株)는 complete media에서 생성(生成)한 protease 활성(活性)은 식염농도(食鹽濃度) 7%에서 약간 조해(阻害)를 받아 활성(活性)이 $10{\sim}30%$가 감소(減少)하였고 Sarcina litoralis 8-14 및 8­16 양균주(兩菌株)는 동배지(同培地)에서 생성(生成)한 protease 활성(活性)은 식염농도(食鹽濃度) 7%에서 그 발효활성(醱酵活性)의 $10{\sim}20%$가 감소(減少)하였다. c) 젓갈 원료중(原料中)의 단백질(蛋白質)은 자가효소(自家酵素)에 의한것보다 주(主)로 젓갈숙성중(熟成中) 관여미생물(關與微生物)의 protease에 의(依)한 가수분해(加水分解)로 유리(遊離) amino 산(酸)이 생성(生成)됨을 알 수 있었다. d) 젓갈원료(原料) 및 젓갈의 RNA-depolymerase는 젓갈중(中) RNA를 nucleoside 및 유리인산(遊離燐酸)까지 분해(分解)하므로 정미성(呈味性) 5'-mononucleotide로서 축적(蓄積)되기 어렵다 e) 조개젓에서 분리(分離)한 Bacillus subtilis 3-6 균주(菌株)가 생성(生成)한 효소(酵素)는 RNA를 분해(分解)하여 5’-mononucleotide로 축적(蓄積)하므로 이 균주(菌株)가 생성(生成)한 RNA 분해효소(分解酵素)는 5’-phosphodiesterase임을 밝혔다. f) Bacillus subtilis 3-6 strain의 효소생성배지중(酵素生成培地中)에 corn steep liquor 0.5% 농도(濃度)로 첨가(添加)한 구(區)와 조개젓 0.5% 농도(濃度)로 첨가(添加)한 구(區)에서 5’-phosphodiesterase 생성증가(生成增加)를 보았으므로 corn steep liquor 및 조개젓 성분(成分)이 각각(各各) 5’-phosphodiesterase 생성증가제(生成增加劑)가 됨을 밝혔으며 또한 이 효소(酵素)는 10%의 식염농도(食鹽濃度)에서 활성조해(活性阻害)를 받아 $10{\sim}30%$에 해당(該當)되는 활성(活性)이 감소(減少)되었고 식염농도(食鹽濃度) 20%에서 이 효소활성(酵素活性)의 $40{\sim}60%$가 감소(減少)함을 나타냈다. 그리고 이 균주(菌株)의 5’­phosphodiesterase에 의(依)하여 젓갈중(中) 5’-mononucleotides가 생성(生成)되는 것이라고 생각된다. (3) 젓갈의 유리(遊離) amino 산(酸)을 Autoanalyzer로 정량(定量)한 결과(結果)는 다음과 같다. a) 조개젓은 산성(酸性) amino 산(酸)인 glutamic acid, asp artic acid 함량(含量)이 다른 젓갈보다 $2{\sim}10$배(倍) 정도(程度)로 현저하게 많아서 조개젓의 구수한 맛이 발현(發現)되는 것이라고 생각(生覺)된다. b) 조기젓에는 basic amino acid인 arginine, histidine함량(含量)이 다른 젓갈보다 특이(特異)하게 많았다. c) 오징어젓은 함류황(含硫黃) amino산(酸)인 cystine함량(含量)이 다른 젓갈의 $17{\sim}130$배(倍), methionine함량(含量)이 $7{\sim}17$배정도(倍程度)로 현저하게 많았다. d) 굴젓에는 필수(必須) amino 산(酸)인 lysine, threonine iso leucine, leucine 함량(含量)이 다른 젓갈보다 현저하게 많을 뿐아니라 또한 감미성(甘味性) amino 산(酸)인 alanine 함량(含量)이 다른 젓갈들보다 4배(倍), glycine 함량(含量)이 $3{\sim}14$배정도(倍程度)로 함유(含有)하고 있어 이것이 굴젓 특유(特有)의 단맛을 발현(發現)하는 것이라 생각(生覺)된다. (4) 4종(種) 젓갈에 대(對)한 5'-mononucleotide를 ion exchange column chromatography로 측정(測定)한 결과(結果)는 다음과 같다. a) 조개젓에는 5'-adenylic acid, 3’-adenylic acid 가 많이 들어있고 5'-inosinic acid가 미량(微量)들어 있다. b) 굴젓에는 5'-adenylic acid와 3’-adenylic acid가 다른 mononucleotides보다 현저하게 많았다. c) 오징어젓에는 5'-adenylic 및 3'-adenylic acid만이 함유(含有)되어 있는데 이것은 패류(貝類)의 젓갈들과 같 이 무척추연체동물(無脊椎軟體動物)이며 이것들은 adenylic deaminase가 결여(缺如)되어 있어 mononucleotide중(中) adenylic acid의 함량(含量)이 높아 adenylic acid-type 임을 알았다. d) 조기젓 중(中)에는 5'-inosinic acid 함량(含量)이 다른젓갈보다 현저하게 많았으므로 이것은 다른 척추동물(脊椎動物)의 어육(魚肉)이나 수육(獸肉)과 같이 adenylic deaminase가 있어 5'-inosinic acid가 많은 inosinic acid-type임을 알았다. (5) 정미성(呈味性) amino 산(酸) 및 5'-mononucleotide의 조성(組成)과 함량(含量)으로 맛의 조화성(調和性)을 비교(比較)하여 보면 다음과 같다. a) 조기젓은 glutamic acid와 aspartic acid가 풍부(豊富)하고 소량(小量)의 5'-inosinic acid가 공존(共存)된 상태(狀態)이므로 정미성분조성(呈味成分組成)과 함량(含量)이 잘 조화(調和)되어 구수한 맛의 상승작용(相乘作用)이 적당(適當)하게 발현(發現)됨을 구명(究明)하였다. b) 조개젓의 맛은 정미성(呈味性) 5’-mononucleotides에서 유래(由來)되는것 보다는 현저하게 많이 들어있는 glutamic acid 및 aspartic acid에 기인됨을 알았다.

• Biomolecules & Therapeutics
• /
• 제11권1호
• /
• pp.41-50
• /
• 2003

General pharmacological properties of DA-8159, a new pyrazolopyrimidinone derivative were examined in laboratory animals to investigate its safety profile. The oral administration of DA-8159 (1, 5 or 30 mg/kg) in mice and rats had no effect on general behaviors and central nervous system of the animals in test systems, such as hexobarbital-induced sleeping time, motor coordination, normal body temperature, writhing syndromes induced by 0.75% acetic acid solution, chemo-shock produced by pentetrazole solution and rotar rod test. Anesthetized cats treated intravenously with DA-8159 (0.1, 0.3, 1, 3 or 10 mg/kg) showed transient and mild decrease in blood pressure. However, heart rate, respiration rate and tidal volume were not changed by intravenous DA-8159. In the isolated organs including ileum, heart (sinus rate of atria and contractility of papillary muscle), trachea of guinea pigs and phrenic nerve of rats, DA-8159 ($10^{-8}$ ∼$10^{-5}$ mg/L) did not elicit any effect or inhibitory action on the chemically or electrically stimulated contraction. DA-8159 did not influence gastric secretion, pH and total acid output in rats and intestinal propulsion in mice. The administration of DA-8159 in rats had no effect on the platelet aggregation induced by ADP in rabbit plasma, urinary volume and electrolyte ion ($Na^{+}$, $K^{+}$, $Cl^{-}$) excretion in rats. Prothrombin time (PT) of the rats showed a mild but significant increase after administration of DA-8159. Activated partial thromboplastin time (APTT), however, was not affected by DA-8159. These results indicate that DA-8159 does not exert any of serious pharmacological effects.

• 한국임상약학회지
• /
• 제11권1호
• /
• pp.7-12
• /
• 2001

Cilostazol has both antithrombotic and cerebral vasodilating effects, and one of the mechanism is the selective inhibition of platalet cyclic AMP phosphodiesterase. Bioequivalence of two cilostazol tablets, the $Pletaal^{TM}$ (Korea Otsuka Pharmaceutical Co.) and the LG $Cilostazol^{TM}$ (LG Chemical Co.), was evaluated according to the guidelines of Korea Food and Drug Administration (KFDA). Sixteen normal male volunteers ($20\sim29$ years old) were randomly divided into two groups and a randomized $2\times2$ cross-over study was employed. After oral administration of $Pletaal^{TM}$ or LG $Cilostazol^{TM}$ tablet (100 mg cilostazol), blood samples were taken at predetermined time intervals and the serum cilostazol concentrations were determined using an HPLC method with UV/VIS detector. The pharmacokinetic parameters $(AUC_t,\;C_{max}\;and\;T_{max})$ were calculated and ANOVA was utilized for the statistical analysis. The results showed that the differences in AUCt, C_{max} and Tmax between two tablets based on the $Pletaal^{TM}$ tablet were $-5.39\%,\;2.32\%\;and\;4.26\%$, respectively. The powers (1-${\beta}$) for $AUC_t,\;C_{max}\;and\;T_{max}\;were\;83.81\%,\;96.02\%\;and\;91.04%$, respectively. Minimum detectable differences ($\Delta$) and $90\%$ confidence intervals were all less than $\pm20\%$. All these parameters met the criteria of KFDA for bioequivalence, indicating that LG $Cilostazol^{TM}$ tablet is bioequivalent to $Pletaal^{TM}$ tablet.

• Reproductive and Developmental Biology
• /
• 제37권4호
• /
• pp.281-287
• /
• 2013

In mammal, unfertilized oocytes remain in the oviduct or under in vitro culture, which is called "oocyte aging". This asynchrony negatively affects fertilization in pre- and post-implantation embryo development. Caffeine a phosphodiesterase inhibitor is known to rescue oocyte aging in several species. The objective of this study is to determine the cytoskeleton distribution in aged oocytes and the embryo developmental ability of aged oocytes in the present or absence of caffeine during maturation. Caffeine treatment increased the incidence of normal spindle assembly of aged oocytes (treatment, $67.57{\pm}4.11%$ aging, $44.61{\pm}6.4%$) and no significant differences compared to control group. Fluorescence values were compared using ROS (Reactive oxidation species) stain. Fluorescence values appear of control group intensity rate ($51.53.{\pm}3.80$), aging group ($68.10{\pm}5.54$) and treatment of caffeine ($45.04{\pm}2.98$). Aged oocytes that were derived from addition of caffeine to the IVM (in vitro maturation) medium had significantly increased 2-cell that developed to the blastocyst stage compared to the aging group. Blastocysts, derived from caffeine treatment group, significantly increased the total cell number compare aging ($90.44{\pm}10.18$ VS $67.88{\pm}7.72$). Apoptotic fragments of genomic DNA were measured in individual embryo using TUNEL assay. Blastocyst derived from caffeine treatment group decreased significantly the apoptotic index compared to blastocyst derived from aging group. In conclusion, we inferred that the caffeine treatment during oocyte aging can improve the developmental rate and quality in bovine embryos developing in vitro.

• 대한약리학회지
• /
• 제27권2호
• /
• pp.191-196
• /
• 1991

본 연구에서는 흰쥐의 수정란 착상시기에 estradiol이 prostaglandins(PGs) 합성의 전구체인 arachidonic acid를 생성하는데 관여하는 phospholipase $A_2(PLA_2)$의 활성도를 조절하므로써 PGs의 합성을 촉진하는가를 조사하여 다음과 같은 결과를 얻었다. 자궁의 $PLA_2$ 활성도는 수정란이 착상하는 시기인 임신 제 5일에 증가되었으며, 비착상부위에서보다는 착상부위에서 더 높은 것으로 나타났다. Delayed implantation model에서, $PLA_2$ 활성도는 estradiol을 투여한 지 11시간후에 증가되었으며, dbcAMP를 투여한지 8시간후에 증가되었다. 또한 estradiol을 투여하기 2시간전에 phosphodiesterase inhibitor인 theophylline을 투여하면 estradiol만 투여한것에 비하여 $PLA_2$ 활성도가 증가되었다. Estradiol 또는 dbcAMP와 함께 indomethacin을 투여하면 자궁의 PGs합성은 억제되었으나 $PLA_2$ 활성도에는 영향을 주지않았다. 이상의 결과로 보아 흰쥐의 착상시기에 estradiol은 cAMP를 매개로하여 자궁의 $PLA_2$ 활성도를 촉진하므로써 PGs의 합성을 증가시키는 것으로 생각된다.

• Journal of Pharmaceutical Investigation
• /
• 제40권2호
• /
• pp.117-123
• /
• 2010

Ibudilast, 3-isobutyryl-2-isopropyrazolo[1,5-a]pyridine, is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). It preferentially inhibits PDE 3A, PDE4, PDE10 and PDE11 as well as a number of the other PDE families, albeit to a lesser extent. Ibudilast is used clinically to treat bronchial asthma and cerebrovascular disorders. Thes e clinical uses are based on the ability of ibudilast to inhibit platelet aggregation, improve cerebral blood flow and attenuate allergic reactions. The purpose of the present study was to evaluate the bioequivalence of two ibudilast capsules, Ketas capsule (Handok Pharmaceuticals Co., Ltd.) and Pinatos capsule (Sam Chun Dang Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The in vitro release of ibudilast from the two ibudilast formulations was tested using KP Apparatus method with various dissolution media. Twenty six healthy male subjects, 23.31${\pm}$1.09 years in age and 70.45${\pm}$8.51 kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After a single capsule containing 10 mg as ibudilast was orally administered, blood samples were taken at predetermined time intervals and the concentrations of ibudilast in serum were determined using HPLC/UV detector. The dissolution profiles of two formulations were similar in all tested dissolution media. The pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated, and computer programs (Equiv Test and K-BE Test 2002) were utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, Ketas, were 6.99%, -2.48% and 9.93% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., log 0.8791~log 1.1861 and log 0.8347~log 1.1199 for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Pinatos capsule was bioequivalent to Ketas capsule.

• Clinical and Experimental Reproductive Medicine
• /
• 제46권4호
• /
• pp.173-177
• /
• 2019

Objective: We investigated the clinical characteristics of men with testosterone replacement therapy (TRT)-induced hypogonadism and its effect on assisted reproductive technology (ART) in infertile couples. Methods: This study examined the records of 20 consecutive male patients diagnosed with azoospermia or severe oligozoospermia (< 5 × 10⁶/mL) who visited a single infertility center from January 2008 to July 2018. All patients were treated at a primary clinic for erectile dysfunction or androgen deficiency symptoms combined with low serum testosterone. All men received a phosphodiesterase 5 inhibitor and TRT with testosterone undecanoate (Nebido^®) or testosterone enanthate (Jenasteron^®). Patients older than 50 years or with a chronic medical disease such as diabetes were excluded. Results: The mean age of patients was 37 years and the mean duration of infertility was 16.3 ± 11.6 months. At the initial presentation, eight patients had azoospermia, nine had cryptozoospermia, and three had severe oligozoospermia. Serum follicle-stimulating hormone levels were below 1.0 mIU/mL in most patients. Three ongoing ART programs with female factor infertility were cancelled due to male spermatogenic dysfunction; two of these men had normal semen parameters in the previous cycle. After withholding TRT, serum hormone levels and sperm concentrations returned to normal range after a median duration of 8 months. Conclusion: TRT with high-dose testosterone can cause spermatogenic dysfunction due to suppression of the hypothalamic-pituitary-testicular axis, with adverse effects on infertility treatment programs. TRT is therefore contraindicated for infertile couples attempting to conceive, and the patient's desire for fertility must be considered before initiation of TRT in a hypogonadal man.

• Asian-Australasian Journal of Animal Sciences
• /
• 제29권1호
• /
• pp.36-42
• /
• 2016

Milk-related traits (milk yield, fat and protein) have been crucial to selection of Holstein. It is essential to find the current selection trends of Holstein. Despite this, uncovering the current trends of selection have been ignored in previous studies. We suggest a new formula to detect the current selection trends based on single nucleotide polymorphisms (SNP). This suggestion is based on the best linear unbiased prediction (BLUP) and the Fisher's fundamental theorem of natural selection both of which are trait-dependent. Fisher's theorem links the additive genetic variance to the selection coefficient. For Holstein milk production traits, we estimated the additive genetic variance using SNP effect from BLUP and selection coefficients based on genetic variance to search highly selective SNPs. Through these processes, we identified significantly selective SNPs. The number of genes containing highly selective SNPs with p-value <0.01 (nearly top 1% SNPs) in all traits and p-value <0.001 (nearly top 0.1%) in any traits was 14. They are phosphodiesterase 4B (PDE4B), serine/threonine kinase 40 (STK40), collagen, type XI, alpha 1 (COL11A1), ephrin-A1 (EFNA1), netrin 4 (NTN4), neuron specific gene family member 1 (NSG1), estrogen receptor 1 (ESR1), neurexin 3 (NRXN3), spectrin, beta, non-erythrocytic 1 (SPTBN1), ADP-ribosylation factor interacting protein 1 (ARFIP1), mutL homolog 1 (MLH1), transmembrane channel-like 7 (TMC7), carboxypeptidase X, member 2 (CPXM2) and ADAM metallopeptidase domain 12 (ADAM12). These genes may be important for future artificial selection trends. Also, we found that the SNP effect predicted from BLUP was the key factor to determine the expected current selection coefficient of SNP. Under Hardy-Weinberg equilibrium of SNP markers in current generation, the selection coefficient is equivalent to $2^*SNP$ effect.

• Journal of Pharmaceutical Investigation
• /
• 제29권4호
• /
• pp.355-360
• /
• 1999

Triflusal is a new antithrombotic agent which inhibits both platelet cyclooxygenase and c-AMP phosphodiesterase activity. The purpose of the present study was to evaluate the bioequivalence of two triflusal capsules, $Disgren^{TM}$ (Myung-In Pharmaceutical Co., Ltd.) and $Tigriri^{TM}$ (Hana Pharmaceutical Co., Ltd.) according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, $22.94{\pm}1.83$ in age and $63.7l{\pm}10.43$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After one capsule containing 300 mg of triflusal was orally administered, blood was taken at predetermined time intervals and the concentrations of triflusal in serum were determined using HPLC method with UV detector. Pharmacokinetic parameters such as $AUC_t$ $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in $AUC_t$ $C_{max}$ and $T_{max}$ between two capsules were -0.30%, 0.81 % and -3.03%, respectively when calculated against the $Disgren_{TM}$ capsule. The powers $(1-{\beta})$ for $AUC_t$ $C_{max}$ and $T_{max}$ were 98.29%,84.73% and 81.02%, respectively. Minimum detectable differences $({\Delta})$ at ${\alpha}=0.1$ and $1-{\beta}=0.8$ were all less than 20% (e.g., 12.91%, 18.46% and 19.65% for $AUC_t$ $C_{max}$ and $T_{max}$ respectively). The 90% confid,ence intervals were all within ${\pm}20%$(e.g., $-8.97{\sim}8.37$, $-11.58{\sim}13.22$ and $-16.23{\sim}10.17$ for $AUC_t$ $C_{max}$ and $T_{max}$, respectively). All of the above parameters ($1-{\beta}, {\Delta}$ and 90% confidence intervals) met the criteria of KFDA for bioequivalence, indicating that $Tigriri^{TM}$ capsule is bioequivalent to $Disgren^{TM}$ capsule.